Lexaria Bioscience (NASDAQ: LEXX) Appoints New Board Member


Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, announced an addition to its Board of Directors; the company has named industry veteran Catherine Turkel, PharmD, PhD, as its newest member of its board of directors. Turkel brings over two decades of experience as an executive-level leader in early-stage and mid-market pharmaceutical/biotech companies. As Founder and CEO of Nezee Therapeutics, she gained essential expertise and knowledge of space; she was also president and head of research and development for Novus Therapeutics, which was later renamed Eledon Pharmaceuticals Inc. (NASDAQ: ELDN). Currently, she is an Independent Director on the Board of Directors of Object Pharma and a member of the Advisory Board of the non-profit Prostate Cancer Research; she is also an advisory dean at the Chapman University School of Pharmacy. In his various roles, Turkey has led and executed strategic FDA registration and commercial plans as well as global development programs; she has invaluable experience in a range of sectors, including the therapeutic areas of neuroscience, pain, cardiovascular system, psychiatry, rare diseases, ophthalmology, aesthetics, urology and otology. Additionally, Turkel designed and led an innovative BOTOX(R) chronic migraine registration program for Allergan, now AbbVie Inc. (NYSE: ABBV), which generated more than $1 billion. “Lexaria is thrilled to welcome Dr. Turkel on board as we continue to position the company for advancement following our recent successful pre-IND meeting with the Food and Drug Administration,” said Chris Bunka, Chairman of the Board of Lexaria. administration of Lexaria, in the press release. “Catherine’s hands-on development and regulatory expertise will be of increasing value to Lexaria, and we look forward to working with her.”

To view the full press release, visit https://cnw.fm/JroKp

About Lexaria Bioscience Corp.

Lexaria Bioscience’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more efficient oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also demonstrated the ability to deliver certain drugs more efficiently across the blood-brain barrier. Lexaria operates an in-house licensed research laboratory and holds a strong intellectual property portfolio with 27 granted patents and approximately 50 patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com.

NOTICE TO INVESTORS: The latest LEXX news and updates are available from the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is a news service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize company news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full range of corporate communications solutions. As a multi-faceted financial news and content distribution company with an extensive team of reporters and editors, CNW is uniquely positioned to better serve private and public companies seeking to reach a wide audience of investors. , consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 major syndication outlets across the country. By reducing the information overload in today’s marketplace, CNW provides its clients with unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (US cell phones only)

For more information, please visit https://www.CannabisNewsWire.com

Please review the full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever posted or republished: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our editor

CannabisNewsWire (CNW)
Denver, Colorado
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.



Comments are closed.